New medical research and innovative therapies are offering fresh hope to millions of people worldwide who suffer from migraine, a severe neurological condition that remains difficult to treat despite its widespread impact.
Migraine affects more than one billion people globally and is one of the leading causes of disability. Patients experience intense headaches along with symptoms such as dizziness, nausea, sensitivity to light and sound, and, in some cases, visual disturbances known as aura. The condition varies greatly from person to person, making treatment complex and often unpredictable.
In the United Kingdom, 35 year old solicitor Megan Daniels uses a small handheld neuromodulation device several times a day to reduce migraine attacks. The device sends mild electrical pulses to stimulate nerves in her neck and face. Daniels says the treatment feels calming and helps prevent attacks as well as reduce their severity.
Neurologists say this type of nerve stimulation is part of a growing range of non drug therapies aimed at disrupting pain pathways in the brain. Such devices are especially useful for patients who do not respond well to medication or cannot take certain drugs due to pregnancy or side effects.
For decades, migraine treatment relied mainly on painkillers and drugs originally developed for other conditions, including heart disease, depression and epilepsy. While these medicines help some patients, others experience little benefit or suffer strong side effects. Overuse of painkillers can also worsen migraine, turning occasional attacks into chronic ones.
A major breakthrough came with the discovery of calcitonin gene related peptide, or CGRP, a small protein involved in pain signaling in the brain. Scientists found that CGRP levels rise during migraine attacks and that blocking this peptide can reduce symptoms.
Several CGRP targeting drugs are now available and have significantly expanded treatment options. Studies show that many patients experience fewer attacks over time, and some see major improvements after long term use. However, experts caution that these drugs do not work for everyone and are not a complete cure.
Daniels, who suffers from vestibular migraine that affects balance, initially responded well to CGRP blockers. But after several months, her symptoms returned. She described being unable to walk properly, drive or leave her home during severe attacks.
Researchers are now exploring other peptides linked to migraine, including PACAP and orexins, which are involved in sleep and brain signaling. New drugs targeting these molecules are currently in clinical trials and may offer additional preventive options.
Another effective treatment has come from an unexpected source. Botox, widely used for cosmetic purposes, has been shown to reduce migraine frequency when injected around the head and neck. Doctors later discovered that Botox works by blocking the release of CGRP in sensory nerves rather than relaxing muscles alone. Many chronic migraine patients see their attacks cut by half after regular treatment.
In more severe cases, doctors are turning to mechanical therapies. These include wearable devices placed on the neck, forehead, arm or head that deliver electrical or magnetic pulses to calm overactive nerves. Experimental devices are also being developed that use gentle vibrations inside the nose to reduce inflammation linked to migraine pain.
Experts stress that no single treatment works for all patients. Instead, migraine care increasingly combines medication, nerve stimulation, lifestyle changes and psychological support. Good sleep habits, diet, exercise, stress management and therapies such as mindfulness and cognitive behavioural therapy are now considered important parts of long term care.
Neurologists say understanding migraine as a chronic brain condition rather than just a headache is key to improving quality of life. While a complete cure remains elusive, the expanding range of treatments means patients today have more options than ever before to manage this disabling condition.
With inputs from BBC